Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Angelo Belotti, Rossella Ribolla, Claudia Crippa, Marco Chiarini, Viviana Giustini, Samantha Ferrari, Annalisa Peli, Chiara Cattaneo, Aldo Roccaro, Barbara Frittoli, Marta Salis, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 1140–1141.

https://doi.org/10.1182/blood-2022-157520

Published: 2022

Journal Articles

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Angelo Belotti, Rossella Ribolla, Alberta Villanacci, Marco Chiarini, Viviana Giustini, Giulia Vittoria Facchetti, Claudia Crippa, Valeria Cancelli, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Chiara Saeli, Aldo M. Roccaro, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2021-147694

Published: 2021

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-137412

Published: 2020

Journal Articles

External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry

Angelo Belotti, Rossella Ribolla, MD, Valeria Cancelli, MD, Alberta Villanacci, Valentina Angelini, Samantha Ferrari, Annalisa Peli, MD, Chiara Cattaneo, MD, Marco Chiarini, MSc, Luigi Grazioli, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-135969

Published: 2020

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

Journal Articles

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Blood (2019) 134 (Supplement_1): 4321.

https://doi.org/10.1182/blood-2019-125134

Published: 2019

Journal Articles

Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs

Blood (2018) 132 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2018-99-111482

Published: 2018

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Blood (2017) 130 (Supplement 1): 4541.

https://doi.org/10.1182/blood.V130.Suppl_1.4541.4541

Published: 2017

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Blood (2016) 128 (22): 1145.

https://doi.org/10.1182/blood.V128.22.1145.1145

Published: 2016

Journal Articles

Autologous Stem Cell Transplant (ASCT) Improves the Prognosis of AL Amyloidosis By Inducing a Higher Organ Response Rates and May be Preferred As First Line Treatment Both in AL and in AL Associated with Multiple Myeloma (MM)

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, Vincenza Orlando, PharmD, Mariella D'Adda, MD, Alessandro Re, MD, Enrico Morello, MD, Chiara Cattaneo, MD, Giuseppe Rossi

Blood (2016) 128 (22): 4634.

https://doi.org/10.1182/blood.V128.22.4634.4634

Published: 2016

Journal Articles

Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients

Nicola Polverelli, MD PhDstudent, Michele Malagola, MD PhD, Alessandro Turra, MD, Cristina Skert, MD, Federica Cattina, MD PhD, Benedetta Rambaldi, MD, Rossella Ribolla, MD, Valeria Cancelli, MD, Francesca Schieppati, MD, Marta Bonetti, MD, Simona Bernardi, PhD, Simone Perucca, PhD, Camilla Zanaglio, Domenico Russo, MD

Blood (2016) 128 (22): 4601.

https://doi.org/10.1182/blood.V128.22.4601.4601

Published: 2016

Journal Articles

Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression

Angelo Belotti, MD, Michele Malagola, Claudia Crippa, MD, Ilaria Prezioso, Francesca Schieppati, Rossella Ribolla, Vincenza Orlando, Domenico Russo, Giuseppe Rossi, MD

Blood (2015) 126 (23): 2965.

https://doi.org/10.1182/blood.V126.23.2965.2965

Published: 2015

Journal Articles

Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease

Cristina Skert, MD, Alessandro Turra, Michele Malagola, Simone Perucca, Valeria Cancelli, Rosa Daffini, Rossella Ribolla, Cesare Bergonzi, Carla Filì, MD, Chiara Pagani, MD, Andrea Di Palma, Federica Cattina, MD PhD, Simona Bernardi, Domenico Russo, MD PhD

Blood (2014) 124 (21): 3932.

https://doi.org/10.1182/blood.V124.21.3932.3932

Published: 2014

Journal Articles

Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs) Correlate Differently with Graft-Versus-Host Disease and Relapse

Cristina Skert, MD, Simone Perucca, Luisa Imberti, Marco Chiarini, MSc, Michele Malagola, Carla Filì, MD, Cesare Bergonzi, Rossella Ribolla, Valeria Cancelli, Alessandro Turra, Federica Cattina, MD PhD, Andrea Di Palma, Domenico Russo, MD PhD

Blood (2014) 124 (21): 3933.

https://doi.org/10.1182/blood.V124.21.3933.3933

Published: 2014

Journal Articles

WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia

Michele Malagola, Crisitina Skert, Enrico Morello, MD, Francesca Antoniazzi, MD, Erika Borlenghi, MD, Alessandro Turra, Chiara Pagani, MD, Rossella Ribolla, Valeria Cancelli, Federica Cattina, MD PhD, Elisa Alghisi, Simona Bernardi, Simone Perucca, Andrea Di Palma, Giuseppina Ruggeri, Giuseppe Rossi, Luigi Caimi, Domenico Russo, MD

Blood (2014) 124 (21): 3695.

https://doi.org/10.1182/blood.V124.21.3695.3695

Published: 2014

NARROW

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Autologous Stem Cell Transplant (ASCT) Improves the Prognosis of AL Amyloidosis By Inducing a Higher Organ Response Rates and May be Preferred As First Line Treatment Both in AL and in AL Associated with Multiple Myeloma (MM)

Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients

Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression

Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease

Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs) Correlate Differently with Graft-Versus-Host Disease and Relapse

WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only